Newborn Screening Translational Research Network (NBSTRN) Features Mayo Clinic’s Dr. Roshini Abraham
The Newborn Screening Translational Research Network (NBSTRN), a resource for investigators engaged in newborn screening related research, featured Mayo Clinic's Roshini Abraham, Ph.D. in its September "Spotlight Researcher of the Month."
Dr. Abraham is currently a professor of medicine and pathology at the Mayo College of Medicine as well as director of the immunology laboratory at the Mayo Clinic in Rochester, Minnesota. Her formal education and training is in microbiology and
immunology. Dr. Abraham's research interests include clinical laboratory immunology related to immunodeficiencies and laboratory assessment of immune competence
As an author of over 25 peer-reviewed papers and 21 abstracts, Dr. Abraham's published works span a wide range of subjects including newborn screening for severe combined immunodeficiency (SCID), novel infrastructure for research in critically ill neonates and children, as well as the relevance of antibody testing in patients with recurrent infections.
Dr. Abraham’s work in immunology research has significantly impacted research for severe combined immunodeficiencies (SCID), as well as newborn screening for SCID.
The goal of the NBSTRN is to facilitate research to improve the health outcomes of newborns with genetic or congenital disorders through an infrastructure that provides the research community access to robust newborn screening resources. As part of the Newborn Screening Saves Lives Act mandated by Congress, the Hunter Kelly Newborn Screening Program was established, with the NBSTRN Coordinating Center as a key component. The NBSTRN Coordinating Center is funded by a contract to the American College of Medical Genetics and Genomics (ACMG) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH).